
    
      This protocol will evaluate the pursuit of injectable bone antiresorptive treatments or their
      switch to oral biphosphonates, or treatment stop, in the contexte of medical practice.

      The primary end-point is the health-related quality of life (QoL). Secondary endpoints are
      safety, overall survial, the impact of toxicities of the treatment on QoL, and the
      description of supportive care.
    
  